

SOLENO THERAPEUTICS INC  
Form 8-K  
October 22, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**  
**The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):**

**October 16, 2018**

**SOLENO THERAPEUTICS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of incorporation)**

**001-36593**  
**(Commission**  
  
**File Number)**

**77-0523891**  
**(IRS Employer**  
  
**Identification No.)**

Edgar Filing: SOLENO THERAPEUTICS INC - Form 8-K

**1235 Radio Rd #110**

**Redwood City, California 94065**

**(Address of principal executive offices, including zip code)**

**(650) 213-8444**

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(a) Resignation of Director

On October 16, 2018, James Glasheen, MA, PhD resigned as a director from the Board of Directors (the Board ) of Soleno Therapeutics, Inc. (the Company ) as well as from the Compensation Committee of the Board of Directors (the Compensation Committee ) and the Audit Committee of the Board of Directors (the Audit Committee ). The resignation of Dr. Glasheen was not the result of any disagreement with the Company relating to the Company s operations, policies or practices.

In addition, on October 19, 2018, Rajen Dalal resigned from the Compensation Committee and was appointed to serve on the Audit Committee and also appointed as the Chairman of the Nominating and Corporate Governance Committee of the Board of Directors.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**SOLENO THERAPEUTICS, INC.**

Date: October 22, 2018

By: /s/ Anish Bhatnagar, MD  
Anish Bhatnagar, MD  
Chief Executive Officer